Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Metabolism of [14C]-BIIL 284 BS in Healthy Volunteers
NCT02266550Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 1999
- Primary completion
- Oct 1999
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of amelubant in chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF) and asthma, sponsored by Boehringer Ingelheim. Primary endpoints: Rates and routes of excretion of total radioactivity at 216 hours, Concentration of [14C] radioactivity in blood at 216 hours and 10 more. Started Oct 1999; status: completed.
02
Drugs
amelubant
03
Conditions
chronic obstructive pulmonary disease (COPD)cystic fibrosis (CF)asthma
Beyond the preview
Go deeper on NCT02266550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02266550.